Key Highlights
- GSK (LSE:GSK) won Japanese approval for Exdensur (depemokimab) on 6 January 2026 for severe asthma and CRSwNP
- Q2 2026 turnover reached £8.4bn, up 5% at constant currency, with core operating profit up 7%
- Specialty Medicines Revenue grew 14% to £3.8bn, led by HIV and Vaccines
- GSK now expects to start more than 20 phase III trials in 2026, double its previous target
- Unveiled a cost-reduction programme targeting £1.9bn of annual savings by 2029
GSK's pipeline momentum has become the central pillar of its Investment case, and 2026 has brought a steady drumbeat of regulatory and clinical progress. A notable milestone came at the start of the year, when Japan's Ministry of Health, Labour and Welfare approved Exdensur (depemokimab) on 6 January for severe or refractory bronchial asthma and for chronic rhinosinusitis with nasal polyps. GSK (LSE:GSK) describes it as the first and only ultra-long-acting biologic in Japan for these conditions, requiring dosing only twice a year — a potentially meaningful convenience advantage. The Japanese clearance followed approvals in the United States and United Kingdom in December 2025, marking depemokimab as one of the group's most closely watched new respiratory launches.
It is worth being precise about the headline's second claim. GSK has a busy regulatory calendar, but a specific, newly granted US FDA "priority review" could not be independently verified from a primary source for this period, so it should not be treated as confirmed. What is verifiable is a broad thickening of the pipeline and a run of filings and approvals across respiratory, oncology and other areas. Investors should read the story as one of genuine, broad-based pipeline acceleration rather than resting on any single designation.
Q2 results reinforce the growth narrative
The commercial picture supports the ambition. In second-quarter results published on 28 July, GSK reported turnover of £8.4bn, up 5% at constant currency, and core operating profit of £2.8bn, up 7%, beating analyst expectations. Growth was led by Specialty Medicines, up 14% to £3.8bn, with HIV sales rising 10% to £2.1bn and Vaccines up 8% to £2.3bn; General Medicines fell 9%. Alongside the numbers, GSK unveiled a cost-reduction programme targeting £1.9bn of annual savings by 2029, most of which will be reinvested in Research and Development and partly used to cushion the looming Patent cliff on its dolutegravir HIV Franchise from 2028.
Strikingly, the company raised its ambitions for clinical activity, saying it now expects to start more than 20 phase III trials in 2026 — double the previous target of around ten — with seven Assets singled out for acceleration across oncology, respiratory, hepatology and vaccines. For the full year, GSK guided to turnover growth of 3–5% and core operating profit and core earnings-per-share growth of 7–9%, while reiterating a long-term target of some £40bn in annual revenue by 2031.
Strategically, GSK is trying to reposition itself as a research-led biopharma group with a deeper specialty-medicines and vaccines pipeline, reducing reliance on maturing products. The dolutegravir patent cliff is the defining challenge: HIV remains a profit engine, and generic competition later this decade will test whether newer launches and long-acting HIV therapies can Fill the gap. The scale-up in phase III activity is a deliberate bet that a broader pipeline can deliver enough successes to offset that erosion.
The risks are considerable. Drug Development is inherently uncertain, and a larger trial programme means larger absolute spending with no guaranteed returns. Litigation overhangs — including historical product-liability matters — have periodically weighed on sentiment, US drug-pricing and policy pressures are intensifying, and Vaccine Demand has proved volatile. Currency swings and reimbursement decisions add further variability to reported results.
For investors, GSK offers a recovering pipeline, improving profit momentum and a manageable valuation relative to some larger peers, set against the well-flagged dolutegravir cliff. The milestones to watch are readouts from the enlarged phase III programme, the commercial ramp of newer launches such as depemokimab and Blenrep, delivery of the £1.9bn savings plan, and progress towards the 2031 revenue goal. On the evidence of 2026 so far, GSK's pipeline is indeed heating up — the question is how much of that promise converts into durable earnings.






Please wait processing your request...